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2352-3042/Copyright ª 2014, ChongqAbstract The normal growth and development of the skull is a tightly regulated process that
occurs along the osteogenic interfaces of the cranial sutures. Here, the borders of the calvarial
bones and neighboring tissues above and below, function as a complex. Through coordinated
remodeling efforts of bone deposition and resorption, the cranial sutures maintain a state of
patency from infancy through early adulthood as the skull continues to grow and accommodate
the developing brain’s demands for expansion. However, when this delicate balance is
disturbed, a number of pathologic conditions ensue; and if left uncorrected, may result in
visual and neurocognitive impairments. A prime example includes craniosynostosis, or prema-
ture fusion of one or more cranial and/or facial suture(s). At the present time, the only ther-
apeutic measure for craniosynostosis is surgical correction by cranial vault reconstruction.
However, elegant studies performed over the past decade have identified several genes critical
for the maintenance of suture patency and induction of suture fusion. Such deeper under-
standings of the pathogenesis and molecular mechanisms that regulate suture biology may pro-
vide necessary insights toward the development of non-surgical therapeutic alternatives for
patients with cranial suture defects. In this review, we discuss the intricate cellular and mo-
lecular interplay that exists within the suture among its three major components: dura mater,
osteoblastic related molecular pathways and osteoclastic related molecular pathways.
Copyright ª 2014, Chongqing Medical University. Production and hosting by Elsevier B.V. All
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The human skull is formed from nine cranial bones,
including two frontal bones, two parietal bones, two tem-
poral bones, one ethmoid bone, one sphenoid bone, and
one occipital bone. These bones articulate with one
another at joints composed of fibrous tissue, also known as
cranial sutures. The areas where several sutures come into
contact are called fontanelles. The skull contains a number
of sutures, including the sagittal suture, located between
the two parietal bones, the coronal sutures, located be-
tween the two frontal and parietal bones, the metopic
suture, located between the frontal bones, the lambdoid
sutures, located between the supraoccipital and parietal
bones, and the squamosal suture, located between the
temporal, parietal, and sphenoid bones (Fig. 1AeC) During
suture formation, the neighboring bone fronts of the cal-
varial bones come into close proximity to one another. The
bones either abut at the suture site, as is the case at the
sagittal and metopic sutures, or overlap, which occurs at
the coronal and lambdoid sutures.1 In addition to these
cranial sutures, there are also a number of facial sutures
present in the human craniofacial skeleton e however, the
embryology, anatomy, and research pertaining to the facial
sutures are outside the scope of this review.
The human skull begins to form between days 23e26 of
gestation, from both mesoderm- and neural crest-derived
tissues. During development, these sutures remain patent
to allow for the expansion of the cranial vault and the un-
derlying brain. The metopic suture is the first to undergo
fusion at approximately 9 months of age, while the sagittalFigure 1 Three-dimensional computed tomography reconstructi
(AeC) and an 8-week-old patient with sagittal synostosis (EeF). An
Typical skull contour with patent sutures. (CeF) Elongated skull
AF, anterior fontanelle; M, metopic suture; S, sagittal suture; Cor.suture does not fully close until adolescence or later.2,3 As
the calvarial bones continue to grow, cranial sutures also
act as important areas of new bone formation and bone
turnover, and facilitate skull growth in the direction
perpendicular to their suture orientation.
Bone can form in one of two ways: either through
endochondral or intramembranous ossification. Most bones
in the human body undergo endochondral ossification,
whereby mesenchymal stem cells first differentiate into
chondrocytes, which secrete a cartilage matrix that even-
tually undergoes osteoblast-driven ossification. The bones
of the cranial vault, however, undergo intramembranous
ossification, a process that does not have a cartilage in-
termediate. Instead, mesenchymal cells, located between
the dermal mesenchyme and the meninges, differentiate
directly into osteoblasts, which then form bone through the
secretion of an osteoid matrix.
The cranial suture can be thought of as a complex,
composed of the two osteogenic bone fronts on either side
of the suture, the mesenchymal tissue of the suture, the
underlying dura mater, and the overlying pericranium
(Fig. 2).4 The cells in the middle of the mesenchymal tissue
of the suture remain undifferentiated during cranial vault
development, while the cells near the two osteogenic bone
fronts typically become bone through the process of
intramembranous ossification.
The tissues of the cranial suture complex all interact
with one another to allow for proper suture formation
and patency throughout development. In functional terms,
suture formation and development must be in tight syn-
chronicity with underlying organ development to facilitateons of a 4-week-old patient with normal suture development
terior (A & D), vertex (B & E), and lateral (C & F) views. (AeC)
shape associated with fusion of the sagittal suture (arrows).
, coronal suture; Sq., squamosal suture; L, lambdoid suture.
Figure 2 Schematic representation of the cranial suture complex. Two osteogenic bone fronts are bridged by mesenchymal
tissue with associated osteoclasts, osteoblasts, and osteoprogenitor cells. The underlying dura mater and overlying pericranium
also contribute to this functional complex (Figure courtesy of Justine C. Lee, MD, PhD).
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prime example is craniosynostosis, or premature fusion of
one or more cranial and/or facial suture(s), which can
occur in nonsyndromic or syndromic forms (Fig. 1DeF).
Craniosynostosis is a condition affecting approximately one
in 2500 live births worldwide.5e7 Premature fusion of a
cranial suture leads to failed expansion of the skull
perpendicular to the affected suture and compensatory
overgrowth parallel to it.8 Such abnormal expansion can
clinically manifest as craniofacial asymmetries, increased
intracranial pressure, mental delay, severe proptosis,
strabismus, visual and airway compromise, midfacial un-
derdevelopment, and malocclusion. Currently, the only
therapeutic measure for craniosynostosis is surgical
correction.
However, from our growing knowledge about the etio-
pathogenesis of this disease, and more specifically the ge-
netic basis of disease, a number of signaling pathways,
cytokines, and growth factors have been shown to play
important roles in proper cranial vault growth and expan-
sion. Such knowledge may lead to new therapies that may
be adjunctive to, or preclude, surgery.
We will discuss this delicate cellular and molecular
interplay within the suture in its three major components:
dura mater, osteoblastic related molecular pathways and
osteoclastic related molecular pathways.Dura mater related pathways
It has been long known that the dura mater plays some role
in suture patency and closure. Classic studies in which
murine cranial sutures typically programmed not to fuse,
such as the sagittal suture, are transplanted to suture-
fusing dura mater regions and then respond with fusion
point to this critical relationship.9 Similarly, Opperman and
colleagues demonstrated that coronal suture devoid of
underlying dura mater closed by 3 weeks, in contrast to its
natural state to remain patent.10 To this end, dura matercells have been shown to express FGF2, and varying con-
centrations of the TGFb isoforms.9,11 Despite this apparent
relationship, no further elucidation of this interplay has
been made in the clinical context.Osteoblastic related pathways
Over the past several years, our knowledge of the molec-
ular pathways governing suture patency and pathology from
a dural and osteoblastic perspective has grown immensely.
Principally, such discovery has stemmed from the identifi-
cation of altered genetic expression, molecular pathways
and environmental causes in forms of syndromic craniosy-
nostosis. The most well-established signaling pathway
associated with osteoblast differentiation in the context of
suture maturation and disease is the fibroblast growth
factor receptor (FGFR) pathway. This molecular signaling
pathway is quite intricate, comprised of 4 different re-
ceptors and over 22 ligands.12 During in utero development
of the human fetus, expression of FGFR-1, -2, and -3 has
been demonstrated within the cranial sutures.13 Confirming
the significant role of FGF signaling in this context, at least
3 point mutations in FGFR (FGFR2 S252W, FGFR2 C342Y, and
P253R for example) correlate phenotypically with syn-
dromic craniosynostoses such as Apert and Crouzon. Such
mutations alter the level of constitutive receptor activa-
tion, ligand-receptor affinity, and the pattern of splicing
and expression, which may in turn explain not only the
mechanism of premature suture closure and disorder type,
but also the phenotypic variability within each syn-
drome.12,14 Lastly, this significant role has been corrobo-
rated in multiple genetically altered animal models.15e18
Other osteoblastic-related genes have been implicated
in suture homeostasis and disease. Some of these genes
have been elucidated from even more rare craniosynostosis
syndromes, such as Boston-type craniosynostosis (MSX-2, a
homeobox gene located on the long arm of chromosome
5),19,20 Saethre-Chotzen syndrome (haploinsufficiency of
Cranial sutures in development and disease 123the Twist nuclear transcription factor gene),21,22 and cra-
niofrontonasal dysplasia (Eprhin B2),23 to name a few.
Owing to the contribution of osteogenesis genes in the
importance of suture fusion, we more recently reported
findings on a child with quadruplication of the RUNX2 gene,
which encodes the Runt-related transcription factor 2 (aka
core-binding factor subunit alpha-1),24 a transcription fac-
tor essential for osteoblast differentiation.25 It follows that
our patient with overexpression of this gene exhibited
multisutural craniosynostosis, midface hypoplasia and
exorbitism akin to the classic dysmorphisms of the FGFR-
related craniosynostoses.24 In addition to these rare asso-
ciations, transforming growth factor beta (TGFb) super-
family genes such as TGFb2, TGFb3 and bone
morphogenetic proteins (BMPs) all appear to play a role.
More specifically, the expression of TGFb2 has been shown
to be important in a rabbit model of craniosynostosis,26,27
whereas higher expression of TGFb3 has been associated
with suture patency. The same follows for BMP3. Nacamuli
and colleagues found an inverse correlation of BMP3
expression and suture closure over time, suggesting that
this factor aids in suture patency. Interestingly, rat calva-
rial osteoblasts stimulated with FGF2 or co-culture with
nonsuture dural cells led to a decrease in BMP3 mRNA
expression that ranged from 50% to 85%.28 Despite experi-
mental evidence for a role of TGFb superfamily genes in
these animal models, few human cases of TGFb gene mu-
tation have been described that supports this situation in
the clinical scenario.Osteoclastic related pathways
Dissimilar to our knowledge of molecular signaling relevant
to suture osteoblast function, little information exists in
regards to the role of osteoclasts in suture homeostasis
and the signaling factors critical to their function within
the suture. The sparse literature that exists, however,
affirmatively indicates a role of osteoclast activity and su-
ture morphology. Our major hypothesis is based upon the
concept that suture homeostasis relies upon intricate
crosstalk between osteoblasts and osteoclasts at the suture
front. To this end, an exciting link has been made in our
laboratory between immune cells and bone cells, thus
establishing the field of osteoimmunology. The TNF super-
family signaling cascade involving TRANCE (RANK-L), its
receptor RANK, and downstream adaptor proteins, TRAFs,
have been shown to play an important role in osteoimmu-
nology of skeletal homeostasis. RANKL is a factor expressed
not only on activated T cells that mediates dendritic (an-
tigen-presenting cell) survival, but also by osteoblasts,
which modulates osteoclast development and differentia-
tion. It follows that RANKL-deficient (KO) mice lack osteo-
clasts, have marked osteopetrosis with growth plate
defects, resulting in growth retardation in the extremities,
vertebrae and skull.29 Moreover, mice that lack the cell
receptor RANK have a similar phenotype to their ligand-
deficient counterparts, as well as mice that lack one of
the downstream signaling adaptor proteins, TRAF-6.30
Conversely, mice lacking the soluble decoy-receptor,
osteoprotegrin (OPG), which inhibits osteoclastogenesis
in vitro, exhibit osteoporosis of the axial skeleton and havean excess of osteoclasts.31 In none of these reports were
any descriptive or quantitative data produced regarding the
suture morphology in these genetically altered animals.
Additionally, although much research has investigated the
role of immune modulators on skeletal homeostasis, little
information existed in regards to the role of the RANKL-
RANK-TRAF signaling cascade in regards to craniofacial
development and suture biology.
More recently, we have identified a significant role of
osteoclast activation and maintenance in suture biology
through this signaling pathway (Fig. 3).32 Specifically,
sentinel work characterized a temporospatial relationship
between RANK protein expression and physiologic cranial
suture closure in a murine model. Further delineation of
osteoclastic modulators through proteomic and candidate
gene approaches may spawn the development of animal
models for the investigation of nonsyndromic craniosynos-
tosis, as well as molecular-targeted therapies to treat the
clinical disease.
We further used whole organ culture experiments to
determine the effects of RANK blockade on suture homeo-
stasis. When explanted cranial sutures were maintained in
culture, and infected with adenovirus bearing inhibitory
RNA to RANK (siRANK), we found an increase in osseous
bridging in such treated cranial sutures, as exhibited by an
increase in Hounsfield units (HU) by microCT. Additional
studies identifying overexpression of OPG in human cra-
niosynostotic suture samples via Western blot analysis and
failed posterofrontal suture closure in mice deficient in
OPG via microCT, are the focus of another study from our
work (unpublished data), which further implicates this
signaling pathway in the context of suture homeostasis.
A critical feature to the RANK-RANKL-OPG axis is that it
is highly dependent upon post-translational modification
(ubiquitination and phosphorylation) to confer its down-
stream effects. Owing to this fact, Western blot analysis of
protein extracts isolated from human cranial sutures
demonstrated higher expression of ubiquitin-conjugated
(osteoclast activating) TRAF-6 in patent sutures compared
to craniosynostotic sutures (unpublished data).Targeted molecular therapy for
craniosynostosis: a new horizon?
Based on the discovery of multiple pathways described
above, several molecular therapies have been proposed
and tested in animal models of craniosynostosis. The
overwhelming majority of these efforts have been made
towards inhibition of osteoblastic activity and differentia-
tion. To this end, Opperman and colleagues initially
described a pro-patency effect of anti-TGFb2 applied
locally to suturectomy sites in rabbits, which would prevent
the re-synostosis characterized in this animal model.26,27
Interestingly, targeting another member of the TGFb su-
perfamily, landmark work by Warren et al demonstrated
that Noggin, a BMP antagonist, was effective in inhibiting
physiologic posterofrontal suture fusion in mice.33
Furthermore, this inhibitory effect prevented, similar to
the work of Opperman, re-synostosis in suturectomized
mice.34 This mechanistically echoes the pro-inhibitory ef-
fect of BMP3 on this signaling pathway and suture fusion. In
Figure 3 Model for RANK function in cranial suture biology. RANK receptors expressed on osteoclasts trimerize to interact with
RANKL on osteoblasts or other involved cell types delivering survival signals to osteoclasts. In addition, the receptoreligand
complex or posttranslational modification of RANK prevent degradation of the receptor. A secondary role of macrophage colony
stimulating factor potentiates RANK signaling by increasing the expression of RANK and Bcl-1. Decreasing activity downstream of
RANK from protein degradation induces apoptosis. One of the possible mechanisms may involve the presence of the decoy receptor
OPG. Reproduced from J Craniofac Surg. 2011; 22(2):699e705 with permission.
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hibitors have been developed and shown to be relatively
effective in abrogating the FGFR-35 and MEK1-induced36
pro-fusion suture morphology.
Stemming from our discussion above, it is of primary
interest to our group to develop therapies that would
stimulate osteoclast activation, whether through over-
expression of RANK/RANKL or inhibition of OPG. In other
words, we believe that not only osteoblast inhibition, but
also osteoclast activation or both would be an effective
anti-craniosynostotic strategy.
Conclusions and future directions
Cranial suture biology depends on a complex interplay be-
tween bone deposition and resorption. Elegant studies
performed over the past decade have identified several
genes critical for the maintenance of suture patency and
induction of suture fusion. More recently, we have identi-
fied the potential significance of osteoclasts in the suture
microenvironment. Specifically, in our recent studies, the
essential regulators of osteoclastogenesis and osteoclast
activation, RANK and the signaling active form of TRAF6,
correlate to suture patency. Both RANK and TRAF6 are
regulated post-transcriptionally. Furthermore, RANK
knockdown via RNA interference is necessary and sufficient
to induce increases in suture bone density consistent with
fusion suggesting that dysregulation of RANK may serve a
causal role in craniosynostosis. Lastly genetic abrogation of
OPG expression correlates with failure of posterofrontal
suture fusion in knockout mice. Future studies will be
aimed towards proteomic analysis of post-translational
differences between fused and patent suture samples.
Molecular analysis will provide the basis for targetedgenetic/molecular alteration of osteoclasts and will pro-
vide a foundation for targeted therapies in nonsyndromic
craniosynostosis.Conflicts of interest
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